CN102695702A - 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 - Google Patents

用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 Download PDF

Info

Publication number
CN102695702A
CN102695702A CN2010800417753A CN201080041775A CN102695702A CN 102695702 A CN102695702 A CN 102695702A CN 2010800417753 A CN2010800417753 A CN 2010800417753A CN 201080041775 A CN201080041775 A CN 201080041775A CN 102695702 A CN102695702 A CN 102695702A
Authority
CN
China
Prior art keywords
cancer
abt
free base
crystalline
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800417753A
Other languages
English (en)
Chinese (zh)
Inventor
张光中
P.J.布雷克迈尔
N.D.卡特伦
T.B.博尔查德特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN102695702A publication Critical patent/CN102695702A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800417753A 2009-09-20 2010-09-15 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 Pending CN102695702A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24405109P 2009-09-20 2009-09-20
US61/244,051 2009-09-20
PCT/US2010/048949 WO2011034934A1 (en) 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610194338.4A Division CN105820138A (zh) 2009-09-20 2010-09-15 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物

Publications (1)

Publication Number Publication Date
CN102695702A true CN102695702A (zh) 2012-09-26

Family

ID=43064468

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800417753A Pending CN102695702A (zh) 2009-09-20 2010-09-15 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CN201610194338.4A Pending CN105820138A (zh) 2009-09-20 2010-09-15 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610194338.4A Pending CN105820138A (zh) 2009-09-20 2010-09-15 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物

Country Status (15)

Country Link
US (2) US8362014B2 (enExample)
EP (1) EP2477972A1 (enExample)
JP (2) JP2013505249A (enExample)
KR (1) KR20120085781A (enExample)
CN (2) CN102695702A (enExample)
AU (1) AU2010295717B2 (enExample)
BR (1) BR112012006252A2 (enExample)
CA (1) CA2771984A1 (enExample)
IL (1) IL218403A0 (enExample)
MX (1) MX2012003408A (enExample)
NZ (1) NZ598461A (enExample)
RU (1) RU2551376C2 (enExample)
TW (1) TWI488853B (enExample)
WO (1) WO2011034934A1 (enExample)
ZA (1) ZA201202891B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558434T3 (es) 2008-11-07 2016-02-04 Amgen Research (Munich) Gmbh Tratamiento de leucemia linfoblástica aguda
HRP20150400T1 (hr) * 2008-11-07 2015-05-08 Amgen Research (Munich) Gmbh Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
MX2012003408A (es) 2009-09-20 2012-08-03 Abbott Lab Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
CA2780177A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2900322C (en) * 2013-02-21 2019-03-26 Pfizer Inc. Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
JP2016516808A (ja) * 2013-04-21 2016-06-09 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． Ｂｃｌ−ｘＬおよび／またはＢｃｌ−ｗの活性および／または量を下方制御するための薬剤
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
WO2015157120A1 (en) * 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738B (zh) * 2018-08-29 2020-10-16 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
JP7417356B2 (ja) 2019-01-25 2024-01-18 株式会社ソニー・インタラクティブエンタテインメント ロボット制御システム
JP2022553820A (ja) 2019-11-05 2022-12-26 アッヴィ・インコーポレイテッド 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027135A1 (en) * 2005-05-12 2007-02-01 Milan Bruncko Apoptosis promoters
CN101220008A (zh) * 2008-01-21 2008-07-16 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
CN101534904A (zh) * 2006-09-05 2009-09-16 艾博特公司 治疗血小板过量的bcl抑制剂
CN102131792A (zh) * 2008-06-20 2011-07-20 雅培制药有限公司 用于制备凋亡启动子abt-263的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713507A (en) 1948-10-04 1955-07-19 Garlinghouse Brothers Concrete bucket
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7075365B1 (en) 2004-04-22 2006-07-11 Altera Corporation Configurable clock network for programmable logic device
JP4202380B2 (ja) * 2006-10-17 2008-12-24 シャープ株式会社 画像形成装置
CN101939008A (zh) 2007-12-06 2011-01-05 雅培制药有限公司 用于治疗癌症的abt-263经口组合物
US8140876B2 (en) * 2009-01-16 2012-03-20 International Business Machines Corporation Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2010259520A (ja) 2009-04-30 2010-11-18 Motoji Ono 搬送機構、トレッドミル及びコンベア
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20110047552A1 (en) * 2009-05-11 2011-02-24 Raytheon Bbn Technologies Corp. Energy-aware process environment scheduler
US8291422B2 (en) * 2009-05-11 2012-10-16 Bbn Technologies Corp. Energy-aware computing environment scheduler
MX2012003408A (es) 2009-09-20 2012-08-03 Abbott Lab Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027135A1 (en) * 2005-05-12 2007-02-01 Milan Bruncko Apoptosis promoters
CN101534904A (zh) * 2006-09-05 2009-09-16 艾博特公司 治疗血小板过量的bcl抑制剂
CN101220008A (zh) * 2008-01-21 2008-07-16 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
CN102131792A (zh) * 2008-06-20 2011-07-20 雅培制药有限公司 用于制备凋亡启动子abt-263的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEOL-MIN PARK，等: "Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins", 《J. MED. CHEM.》 *
GUANGJUN WANG，等: "An efficient synthesis of ABT-263, a novel inhibitor of antiapoptotic Bcl-2 proteins", 《SYNTHESIS》 *
巫凤娟 等: "《抗癌药ABT-263》", 《药学进展》 *

Also Published As

Publication number Publication date
AU2010295717B2 (en) 2014-09-11
NZ598461A (en) 2013-12-20
AU2010295717A1 (en) 2012-03-22
US20110294811A1 (en) 2011-12-01
TW201116526A (en) 2011-05-16
US20110071151A1 (en) 2011-03-24
US8513243B2 (en) 2013-08-20
KR20120085781A (ko) 2012-08-01
RU2551376C2 (ru) 2015-05-20
MX2012003408A (es) 2012-08-03
IL218403A0 (en) 2012-04-30
CA2771984A1 (en) 2011-03-24
JP2013505249A (ja) 2013-02-14
WO2011034934A1 (en) 2011-03-24
CN105820138A (zh) 2016-08-03
JP2015232006A (ja) 2015-12-24
ZA201202891B (en) 2013-09-25
TWI488853B (zh) 2015-06-21
US8362014B2 (en) 2013-01-29
RU2012115851A (ru) 2013-10-27
BR112012006252A2 (pt) 2017-05-23
EP2477972A1 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
US8362014B2 (en) ABT-263 crystalline forms
US8362013B2 (en) Salt of ABT-263 and solid-state forms thereof
CN102802605B (zh) 凋亡启动子的稳定脂质制剂
US20100278921A1 (en) Solid oral formulation of abt-263
CN103328474A (zh) 细胞凋亡诱导剂的盐和晶形
US8927009B2 (en) ABT-263 capsule
WO2021207581A1 (en) Crystalline forms of an apoptosis-inducing agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130618

Address after: Illinois State

Applicant after: ABBVIE company

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

RJ01 Rejection of invention patent application after publication

Application publication date: 20120926

RJ01 Rejection of invention patent application after publication